Alvotech announces strategic refinancing agreement

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a strategic refinancing transaction. the financing, led by goldentree asset management, with participation from other institutional investors (collectively, the “lenders”), will enable alvotech (the “company”) to improve cost of capital, address upcoming debt maturities in 2025 and enhance its financial flexibility by adding incremental cash to the balance sheet.
ALVO Ratings Summary
ALVO Quant Ranking